Хайлтын үр дүнгүүд - Baek‐Yeol Ryoo
- 52-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
-
2
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker an... -н Changhoon Yoo, Min‐Hee Ryu, Young-Soon Na, Baek‐Yeol Ryoo, Chae-Won Lee, Yoon‐Koo Kang
Хэвлэсэн 2016Artigo -
3
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients -н Bum Jun Kim, Changhoon Yoo, Kyu‐pyo Kim, Jaewon Hyung, Seongjoon Park, Baek‐Yeol Ryoo, Heung-Moon Chang
Хэвлэсэн 2017Artigo -
4
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen -н Changhoon Yoo, Bum Jun Kim, Kyu‐pyo Kim, Jae‐Lyun Lee, Tae Won Kim, Baek‐Yeol Ryoo, Heung-Moon Chang
Хэвлэсэн 2016Artigo -
5
-
6
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... -н Jaekyung Cheon, Shigeo Shimose, Hyung‐Don Kim, Takashi Niizeki, Min‐Hee Ryu, Tomotake Shirono, Baek‐Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
Хэвлэсэн 2025Artigo -
7
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion -н Sang Min Yoon, Baek‐Yeol Ryoo, So Jung Lee, Jong Hoon Kim, Ji Hoon Shin, Jihyun An, Han Chu Lee, Young‐Suk Lim
Хэвлэсэн 2018Artigo -
8
-
9
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma -н J. Lee, Cheolwon Suh, Hye Jin Kang, Baek‐Yeol Ryoo, Jooryung Huh, Young Hyeh Ko, Hyeon‐Seok Eom, Kihyun Kım, K. Park, W. S. Kim
Хэвлэсэн 2008Artigo -
10
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors -н Joo Young Kim, Jisup Kim, Yong-il Kim, Dong‐Hoon Yang, Changhoon Yoo, In Ja Park, Baek‐Yeol Ryoo, Jin‐Sook Ryu, Seung‐Mo Hong
Хэвлэсэн 2024Artigo -
11
Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) -н Michael J. Pishvaian, M.S. Lee, Baek‐Yeol Ryoo, Stacey Stein, Ki Hoon Lee, Wendy Verret, Jessica Spahn, Hui Shao, B. Liu, Kunio Iizuka, Chih‐Hung Hsu
Хэвлэсэн 2018Artigo -
12
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma -н Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim
Хэвлэсэн 2018Artigo -
13
Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study -н Fabio Piscaglia, Kenji Ikeda, Ann‐Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, В. В. Бредер, Baek‐Yeol Ryoo, Kalgi Mody, Min Ren, Zahra Ramji, Max W. Sung
Хэвлэсэн 2024Artigo -
14
Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study -н Dong‐Hoe Koo, Sung‐Cheol Yun, Yong Sang Hong, Min‐Hee Ryu, Jae‐Lyun Lee, Heung-Moon Chang, Baek‐Yeol Ryoo, Yoon‐Koo Kang, Tae Won Kim
Хэвлэсэн 2011Artigo -
15
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis -н Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, Neung Hwa Park, Jung Woo Shin, Kang Mo Kim, Han Chu Lee, Joo‐Ho Lee, Changhoon Yoo, Baek‐Yeol Ryoo
Хэвлэсэн 2020Artigo -
16
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) -н Seyoung Seo, Min‐Hee Ryu, Young Soo Park, Ji Yong Ahn, Yangsoon Park, Sook Ryun Park, Baek‐Yeol Ryoo, Gin Hyug Lee, Hwoon-Young Jung, Yoon‐Koo Kang
Хэвлэсэн 2018Artigo -
17
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, pha... -н Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, Baek‐Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung‐Ho Nam, Nikhil H. Ramaiya, Jyothi P. Jagannathan, George D. Demetri
Хэвлэсэн 2013Artigo -
18
The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors -н Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Baek‐Yeol Ryoo, Im Il Na, Sung Hyun Yang, Seung‐Sook Lee, Cheol Hyeon Kim, Young Yoo, Jae Cheol Lee
Хэвлэсэн 2009Artigo -
19
Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients -н Seung Hee Seo, Sung-Eun Kim, Yoon‐Koo Kang, Baek‐Yeol Ryoo, Min‐Hee Ryu, Jae Ho Jeong, Shin Sook Kang, Mihi Yang, Jung Eun Lee, Mi‐Kyung Sung
Хэвлэсэн 2016Artigo -
20
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) -н Matthew Man Pok Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, B. Liu, Hesham Abdullah, Ruth He, Ki Hoon Lee
Хэвлэсэн 2019Artigo
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Internal medicine
Medicine
Oncology
Gastroenterology
Cancer
Hepatocellular carcinoma
Sorafenib
Chemotherapy
Surgery
Confidence interval
Clinical endpoint
Immunotherapy
Hazard ratio
Colorectal cancer
Adverse effect
Clinical trial
Gemcitabine
Pathology
Phases of clinical research
Alternative medicine
Nivolumab
Placebo
Randomized controlled trial
Atezolizumab
Carcinoma
Lenvatinib
Cancer research
Oxaliplatin
Pancreatic cancer
Bevacizumab